- Company
- Sales of flu treatments have decreased significantly
- by Chon, Seung-Hyun Jan 27, 2022 05:42am
- The outpatient prescription market also fluctuated two years after the landing of COVID-19. Sales in the pharmaceutical market, which is mainly used for infectious diseases such as influenza (flu) treatments, antibiotics, and expectorants, have decreased significantly. The flu treatment market has virtually disappeared. According to UBIST on
- Company
- KRPIA presidents will meet with Lee Joon-seok
- by Eo, Yun-Ho Jan 26, 2022 05:57am
- Ahead of the presidential election, KRPIA and multinational pharmaceutical presidents will meet with the leader of the main opposition party. According to the Dailypharm's confirmation, the presidents of the KRPIA will hold a meeting with Lee Joon-seok, CEO of People's Power, tomorrow morning (27th). The meeting will be attended by Oh Dong
- Company
- Outpatient prescriptions slow for MNCs...Viatris in the lead
- by Jan 26, 2022 05:57am
- Outpatient prescription sales of multinational pharmaceutical companies in Korea had slowed down in general last year. Viatris held the lead among multinational pharmaceutical companies for two consecutive years, but its amount of prescriptions also decreased 0.3% compared to the previous year. The top prescription drug companies such as MSD (Or
- Policy
- PVA price reduction needs to be improved
- by Lee, Jeong-Hwan Jan 26, 2022 05:57am
- .There is a problem that the reduction rate of small items relatively increases compared to the financial impact by using the same formula for PVA negotiations. It was pointed out that the current PVA is operating too rigidly without reflecting the reality that medicines affect health insurance finances. Critics say that drugs that reduce hea
- Company
- SK Bioscience wins 3rd EU-GMP for its vaccine plant
- by Ji Yong Jun Jan 26, 2022 05:57am
- SK Bioscience, which has signed a CMO deal to manufacture the Novavax vaccine, has additional received EU-GMP certification from the European Medicines Agency. This is the third EU-GMP certification the company received. On the 25th, SK Bioscience announced that it had received additional EU-GMP certification for the manufacturing facilit
- Policy
- The presidential candidate's pledge to expand NIP is fierce
- by Lee, Jeong-Hwan Jan 26, 2022 05:57am
- The expansion of free HPV vaccine vaccination is spreading to a competition for pledges of presidential candidates between the ruling and opposition parties. As the ruling party candidate adopted the application of the NIP of the bivalent and HPV vaccine as a pledge, the opposition candidate is fiercely fighting, promising to support the
- Company
- Montelukast sales 22%↓ in 2 years and adds impurity issue
- by Kim, Jin-Gu Jan 25, 2022 05:55am
- The market for the montelukast ingredient used to treat allergic rhinitis and asthma has contracted for two consecutive years. The reduction is analyzed to be due to the combined effect of the US FDA’s side effect warning request for the ingredient in 2020 and the prolonged COVID-19 crisis. Industry eyes are on how the impurity issue that re
- Policy
- The MOHW has won the original drug price lawsuit
- by Lee, Jeong-Hwan Jan 25, 2022 05:55am
- The government won all dozens of lawsuits to cancel drug prices due to the expiration of original drug patents, but no civil lawsuits have been filed to get back drug benefits paid during the suspension period. The government says it is practically impossible to file a civil suit against individual pharmaceutical companies against dozens of d
- Company
- United to complete P2T enrollment for its inhaled Covid drug
- by Lee, Seok-Jun Jan 25, 2022 05:55am
- Korea United Pharm will complete patient enrollment of its Phase II trial for the world’s first inhaled COVID-19 treatment ‘Corobin Activair (budesonide+ arformoterol).’ According to the company on the 24th, Korea United Pharm had been enrolling patients for its trial at specialized COVID-19 hospitals in Seoul to assess the safety and e
- Policy
- MFDS has completed verification of the efficacy of Retevmo
- by Lee, Tak-Sun Jan 25, 2022 05:55am
- The RET (Rearranged during transfection)) gene target anticancer drug developed by Lilly seems to be at the end of the domestic approval process. It is a drug called Retevmo (Selpercatinib), which began licensing last year, and safety and efficiency evaluation have recently been completed and is about to be approved. According to the pharm
